Jun Li

Prof. Dr. Jun Li

university medical center hamburg-eppendorf

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Annals of Surgery
Verified
Journal Article
Closed access
Andrea FrillingAndrea Frilling
Andrea Frilling
GSGeorgios C. Sotiropoulos
Georgios C. Sotiropoulos
ARArnold Radtke
Arnold Radtke
MMMassimo Malago
Massimo Malago
ABAndreas Bockisch
Andreas Bockisch
CBChristoph E. Broelsch
Christoph E. Broelsch
To evaluate the impact of 68Ga-DOTATOC positron emission tomography (PET)/computed tomography (CT) on the multimodal management of neuroendocrine tumors (NET). Establishment of the extent and progression of NET are necessary to decide which treatment option to choose. However, morphological imaging with CT or magnetic resonance imaging (MRI) is often inadequate in identifying the primary tumor and/or in detecting small metastatic lesions. In total, 52 patients (27 women and 25 men) with histologically proven NET could be included in the protocol of comparison between 68Ga-DOTATOC PET/CT and CT and/or MRI. The examinations were performed in terms of tumor staging and, in some instances, also of primary tumor site identification to evaluate the patient's eligibility for treatment. Each patient presented with either CT and/or MRI performed elsewhere and consecutively underwent 68Ga-DOTATOC PET/CT in our institution. In all 52 patients, 68Ga-DOTATOC PET/CT demonstrated pathologically increased uptake for at least 1 tumor site, yielding a sensitivity of 100% on a patient basis. In 3 of 4 patients with unknown primary tumor site, 68Ga-DOTATOC PET/CT visualized the primary tumor region (jejunum, ileum, and pancreas, respectively) not identified on CT and/or MRI. 68Ga-DOTATOC PET/CT detected additional hepatic and/or extrahepatic metastases in 22 of the 33 patients diagnosed with hepatic metastases on CT and/or MRI. Of the 15 patients evaluated for liver transplantation, we omitted 7 (46.6%) from further screening because of evidence of metastatic deposits not seen by conventional imaging. Overall, 68Ga-DOTATOC PET/CT altered our treatment decision based on CT and/or MRI alone, in 31 (59.6%) of the 52 patients. In this study, 68Ga-DOTATOC PET/CT proved clearly superior to CT and/or MRI for detection and staging of NET. More important, 68Ga-DOTATOC PET/CT impacted our treatment decision in more than every second patient.

1 November 2017 in Annals of Surgery
Verified
Journal Article
Closed access
PDF file
MLMichael Linecker
Michael Linecker
BBBergthor Björnsson
Bergthor Björnsson
GSGregor A. Stavrou
Gregor A. Stavrou
KOKarl J. Oldhafer
Karl J. Oldhafer
Georg LurjeGeorg Lurje
Georg Lurje
HPHenrik Petrowsky
Henrik Petrowsky
To longitudinally assess whether risk adjustment in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) occurred over time and is associated with postoperative outcome. ALPPS is a novel 2-stage hepatectomy enabling resection of extensive hepatic tumors. ALPPS has been criticized for its high mortality, which is reported beyond accepted standards in liver surgery. Therefore, adjustments in patient selection and technique have been performed but have not yet been studied over time in relation to outcome. ALPPS centers of the International ALPPS Registry having performed ≥10 cases over a period of ≥3 years were assessed for 90-day mortality and major interstage complications (≥3b) of the longitudinal study period from 2009 to 2015. The predicted prestage 1 and 2 mortality risks were calculated for each patient. In addition, questionnaires were sent to all centers exploring center-specific risk adjustment strategies. Among 437 patients from 16 centers, a shift in indications toward colorectal liver metastases from 53% to 77% and a reverse trend in biliary tumors from 24% to 9% were observed. Over time, 90-day mortality decreased from initially 17% to 4% in 2015 (P = 0.002). Similarly, major interstage complications decreased from 10% to 3% (P = 0.011). The reduction of 90-day mortality was independently associated with a risk adjustment in patient selection (P < 0.001; OR: 1.62; 95% CI: 1.36–1.93) and using less invasive techniques in stage-1 surgery (P = 0.019; OR: 0.39; 95% CI: 0.18–0.86). A survey indicated risk adjustment of patient selection in all centers and ALPPS technique in the majority (80%) of centers. Risk adjustment of patient selection and technique in ALPPS resulted in a continuous drop of early mortality and major postoperative morbidity, which has meanwhile reached standard outcome measures accepted for major liver surgery.

1 May 2013 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
Jun LiJun Li
Jun Li
PGPaolo Girotti
Paolo Girotti
IKIngmar Königsrainer
Ingmar Königsrainer
RLRuth Ladurner
Ruth Ladurner
AKAlfred Königsrainer
Alfred Königsrainer
SNSilvio Nadalin
Silvio Nadalin

1 August 2010 in HPB
Verified
Journal Article
Closed access
PDF file
Andrea FrillingAndrea Frilling
Andrea Frilling
GSGeorgios C. Sotiropoulos
Georgios C. Sotiropoulos
Jun LiJun Li
Jun Li
OKOskar Kornasiewicz
Oskar Kornasiewicz
UPUrsula Plöckinger
Ursula Plöckinger

13 January 2014 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
SNS. Nadalin
S. Nadalin
ICI. Capobianco
I. Capobianco
Jun LiJun Li
Jun Li
PGP. Girotti
P. Girotti
IKI. Königsrainer
I. Königsrainer
AKA. Königsrainer
A. Königsrainer
Introduction: The ALPSS procedure has been recently introduced as an alternative to PVE for liver volume augmentation in cases of planned right trisectionectomy with small future RLV and high risk of PHLF. We retrospectively analysed our single centre experience with 15 ALPPS procedures in order to better assess the limits and indications of the procedure. Patients and Methods: The following volumetric parameters were evaluated: total liver volume (TLV), remnant liver volume (RLV), remnant liver volume to total liver volume ratio (RLV/TLV), remnant liver volume to body weight ratio (RLV/BWR) and median volume gain. The ALPPS procedure was usually considered when RLV/TLV < 25 % or RLV/BWR < 0.5. The ALPPS procedure consisted of phase 1 (in situ splitting of the liver), interphase (waiting for liver regeneration) and phase 2 (completion of right trisectionectomy). Postoperative complications were reported according to the Dindo–Clavien classification. Patient survival, late complications and tumour recurrence were analysed. Results: Between November 2010 and September 2013, we performed 15 ALPPS procedures in 10 patients with primary liver tumours (5 h-CCA, 4 i-CCA and 1 HCC) and in 5 with CRLM. The preoperative RLV/TLV ratio was 22.6 % (15.7 − 29.2) and the RLV/BWR 0.46 (0.22 − 0.66). After 10 days (range 8 − 16) the RLV/TLV ratio and RLV/BWR increased up to 36.3 % (30 − 59.2 %) and 0.67 (0.5 – 1.2) respectively, with a median volume gain of 87.2 % (23.8 − 161 %). The time interval between phases 1 and 2 was 13 days (9 − 18). An R0 status was reached in 13 patients and R1 in 2. The overall postoperative morbidity was 66.7 %. After phase 1, 8 patients experienced 19 complications and 7 none. After phase 2, 11 patients experienced 36 complications and 4 none. Four patients died postoperatively after 22 days (9 − 36 days) resulting in a postoperative mortality of 28.7 %. After a median follow-up of 17 months (1 − 33), 10 out of 15 patients are still alive (survival rate 66.6 %). Four patients (2 i-CCA, 1 CRLM, 1 HCC) developed tumour recurrences (2 intrahepatic and 2 extrahepatic). One patient with i-CCA died at POM 4 secondary to peritoneal carcinosis. Discussion: The actual high morbidity and mortality rates related to the ALPPS procedure should lead us to a more cautious selection of the candidates for this operation and restriction of the indications through an accurate work-up based on interdisciplinary cooperation among hepatologists, oncologists, radiologists and surgeons. Einleitung: Das ALPSS-Verfahren wurde als Alternative zur PVE für die Augmentation des Lebervolumens bei geplanten erweiterten Hemihepatektomie rechts mit kleinem zukünftigen Restlebervolumen (RLV) und entsprechenden hohen Risiko für Post-Hepatektomie-Leberversagen (PHLF) eingeführt. Durch eine retrospektive Analyse der an unseren Zentrum durchgeführten 15 ALPPS-Verfahren, möchten wir die Grenze und Indikationen der Prozedur überprüfen. Patienten und Methoden: Folgende volumetrische Parameter wurden ausgewertet: TLV, RLV, RLV/TLV, RLVBWR und Lebervolumengewinn. Bei RLV/TLV < 25 % oder RLVBWR < 0,5 wurde ein ALPPS-Verfahren geplant. Es bestand aus Phase 1 (In-Situ Splitten der Leber), Zwischenphase (Warten auf die Leberregeneration) und Phase 2 (Komplettieren der erweiterten Hemihepatektomie rechts). Postoperative Komplikationen wurden nach Dindo-Clavien klassifiziert. Patientenüberleben, Spätkomplikationen und Tumorrezidiv wurden untersucht. Ergebnisse: Zwischen November 2010 und September 2013 führten wir 15 ALPPS-Verfahren in 10 Patienten mit primären Lebertumoren (5 h-CCA, 4i -CCA und 1 HCC) und in 5 mit CRLM durch. Das präoperative RLV/TLV-Verhältnis betrug 22,6 % (15,7 − 29,2 %) und das RLVBWR 0,46 (0,22 − 0,66). Zehn Tage (8 − 16) nach Phase 1 das RLV/TLV-Verhältnis und das RLVBWR anstieg jeweils bis 36,3 % (30 − 59,2 %) und 0,67 (0,5 − 1,2). Der Volumengewinn war 87,2 % (23,8 − 161 %). Der Zeitabstand zwischen den Phasen 1 und 2 betrug 13 Tage (9 − 18). Eine R0-Status wurde bei 13 Patienten erreicht und R1 in 2 (beide mit h-CCA). Die postoperative Morbidität betrug 66,7 %. Nach Phase 1 erlebten 8 Patienten 19 Komplikationen und 7 keine. Nach Phase 2 erlebten 11 Patienten 36 Komplikationen und 4 keine. Vier Patienten starben 22 Tage (9 − 36) nach Phase 2 (postoperative Mortalität 28,7 %). Nach 17 Monaten (1 − 33), sind noch 10 von 15 Patienten am Leben (Überlebensrate 66,6 %). Vier Patienten (2 i-CCA, 1 CRLM, 1 HCC) entwickelten ein Tumorrezidiv (2 intra- und 2 extrahepatisch). Ein Patient mit i-CCA starb am POM 4 mit Peritonealkarzinose. Diskussion: Die aktuelle hohe Morbiditäts- und Mortalitätsrate des ALPPS-Verfahrens soll uns zu einer sorgfältigen Selektion der Kandidaten und Einschränkung der Indikationen durch eine enge Zusammenarbeit zwischen Hepatologen, Onkologen, Radiologen und Chirurgen führen.

9 February 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CZChong Zhang
Chong Zhang
XWXiang-Yu Wang
Xiang-Yu Wang
JZJie-Liang Zuo
Jie-Liang Zuo
XWXue-Fu Wang
Xue-Fu Wang
XFXiao-Wen Feng
Xiao-Wen Feng
JCJinhong Chen
Jinhong Chen
Background: Tertiary lymphoid structures (TLSs) have been proposed to assess the prognosis of patients with cancer. Here, we investigated the prognostic value and relevant mechanisms of TLSs in colorectal cancer liver metastases (CRCLM). Methods: 603 patients with CRCLM treated by surgical resection from three cancer centers were included. The TLSs were categorized according to their anatomic subregions and quantified, and a TLS scoring system was established for intratumor region (T score) and peritumor region (P score). Differences in relapse-free survival (RFS) and overall survival (OS) between groups were determined. Multiplex immunohistochemical staining (mIHC) was used to determine the cellular composition of TLSs in 40 CRCLM patients. Results: T score positively correlated with superior prognosis, while P score negatively associated with poor survival (all p<0.05). Meanwhile, T score was positively associated with specific mutation subtype of KRAS. Furthermore, TLSs enrichment gene expression was significantly associated with survival and transcriptomic subtypes of CRCLM. Subsequently, mIHC showed that the densities of Treg cells, M2 macrophages and Tfh cells were significantly higher in intratumor TLSs than in peritumor TLSs (p=0.029, p=0.047 and p=0.041, respectively), and the frequencies of Treg cells and M2 macrophages were positively correlated with P score, while the frequencies of Tfh cells were positively associated with T scores in intratumor TLSs (all p<0.05). Next, based on the distribution and abundance of TLSs, an Immune Score combining T score and P score was established which categorized CRCLM patients into four immune classes with different prognosis (all p<0.05). Among them, patients with higher immune class have more favorable prognoses. The C-index of Immune Class for RFS and OS was higher than Clinical Risk Score statistically. These results were also confirmed by the other two validation cohorts. Conclusions: The distribution and abundance of TLSs is significantly associated with RFS and OS of CRCLM patients, and a novel immune class was proposed for predicting the prognosis of CRCLM patients.